← board
ASBPW
distress 5/10 · elevated risk$0.02+5%today-96% from 52w high
Revenue
pre-revenue
Liquidity
$6M
Runway
0.8 yrs
Shares 1y
-97%
Price & events
+5.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+5.0%
1D
-12.1%
1W
+5.0%
1M
+5.0%
3M
—
6M
—
1Y
—
2Y
—
5Y
+5.0%
All
Overview
- Market Cap
- $27.20K
- Volume
- 100
- 52 Week Range
- $0.02 – $0.60
- Total Shares
- 1.30M
- Float Shares
- 1.22M
- RVOL
- 0.25x
- Beta
- 0.15
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2025regulatory submissionFiled (NDA/BLA)high-dose aspirin · Potential FDA submission via 505(b)(2) pathway supported by ongoing clinical trial.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-07-20Aspire Biopharma appoints Jarryd McNeil as sponsored athlete for BUZZ BOMB - TipRanks
- 2026-07-20Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) Files 8-K for July 2026 – Company Details, Stock & Warrants Information – Minichart - Minichart
- 2026-07-20Aspire Biopharma Updates Public Warrant Exercise Terms - TipRanks
- 2026-07-20Aspire Bi clarifies public warrant terms after two reverse stock splits; exercise price now $13,800 - TradingView
- 2026-07-20Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMB(TM) - Black Hills Pioneer
- 2026-07-20Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMB(TM) - Yahoo Finance
- 2026-07-12Aspire Biopharma Holdings Inc (ASBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
- 2026-07-07Price to book forward of Aspire Biopharma Holdings, Inc. – NASDAQ:ASBPW - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.